Frequency and Economic Impact of Comorbid Cardiac Conditions with Multiple Sclerosis

BACKGROUND: Fingolimod, an oral immunomodulatory therapy approved to treat multiple sclerosis (MS) is contraindicated in patients with certain cardiac conditions, yet the frequency of these conditions in patients with MS is not known. This study assessed the frequency and economic impact of cardiac...

Descripción completa

Detalles Bibliográficos
Autores principales: Franklin, Meg A., Happe, Laura E., Dillman, Rachel, Marshall, Landon Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2014
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437308/
https://www.ncbi.nlm.nih.gov/pubmed/25062072
http://dx.doi.org/10.18553/jmcp.2014.20.8.795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437308/
https://www.ncbi.nlm.nih.gov/pubmed/25062072
http://dx.doi.org/10.18553/jmcp.2014.20.8.795

Ejemplares similares